NV-WESTFALL-TECHNIK
2.7.2021 20:24:05 CEST | Business Wire | Press release
Westfall Technik, Inc. (“Westfall”, the “Company”), a global holding company that provides superior manufacturing solutions for the production of plastic parts in the medical, packaging, and consumer goods industries, announced today the acquisition of Carolina Precision Plastics, LLC (d/b/a “CPP Global” or “CPP”) and its wholly owned subsidiaries.
The deal greatly strengthens Westfall’s geographic footprint by adding its first plants in the southeastern United States, specifically in Mocksville and Asheboro, NC, as well in Kaiping, China, in Guangdong Province. “This provides a further supply-chain advantage to Westfall when it comes to serving key customers in both the packaging and healthcare sectors,” said Merritt Williams, the firm’s Chief Commercial Officer. “CPP’s North Carolina plants are ideally located to serve the multitude of brand owners with a manufacturing presence in the surrounding area.”
CPP, which runs about 100 injection molding machines in its three facilities, also brings expertise in vital secondary services, such as high-volume, fully automated assembly and sophisticated decorating capabilities. In total, CPP’s three plants cover some 335,000 square feet of manufacturing space.
“This is just the next step in creating a truly world-class molding and tooling business that is built on a strong culture and unquestionable customer service,” according to Westfall CEO and founder Brian Jones.
A leader in North America in the injection molding of heavy-wall PET jars, CPP also operates an innovative, collaborative design center and has a strong sustainability profile. The firm is a significant user of recycled resins and biopolymers in its products.
“This highly strategic, synergistic deal greatly strengthens our presence in the fast-moving consumer goods segment,” said Mark Gomulka, Westfall’s Chief Operating Officer. “CPP Global is a valued packaging supplier to several leading personal care and beauty companies, such as L’Oréal (serving their L’Oréal Paris and Kiehl’s brands), Estée Lauder, and Burt’s Bees, among others.”
For CPP Chief Executive Officer Brian Tauber, the partnership with Westfall offers a clear path forward for continuing the upward growth trend that CPP Global is experiencing right now. “I’m thrilled to combine our strengths with the breadth and depth of Westfall’s capabilities to enhance our ability to provide our employees, customers, and other stakeholders with more opportunities to grow together,” said Tauber.
The terms of the investment were not disclosed. Westfall was represented by Morrison Cohen LLP as legal counsel. CPP Global was represented by Sheppard, Mullin, Richter & Hampton LLP as legal counsel and Stifel as financial advisor.
About Carolina Precision Plastics, LLC
Carolina Precision Plastics is a global plastic injection molder in the beauty care, cosmetics, beverage and consumer goods markets, providing its customers molding, assembly and decorating capabilities built on a foundation of an industry-leading lean culture. Its global manufacturing presence and commitment to a more sustainable packaging future afford customers the most efficient and environmentally responsible options for their packaging needs. Central to its Lean North Stars, CPP’s journey focuses on providing value to its customers and ensuring a safe, satisfying work environment to its entire team. For more, visit www.cppglobal.com .
About Westfall Technik, Inc.
Westfall Technik is a global holding company that provides highly productive plastics manufacturing solutions to the medical, consumer packaging and consumer goods industries. Since its founding in Las Vegas in October 2017, the company has acquired or launched at least 19 businesses across North America. Westfall Technik’s competitive advantages include modern automated systems, correlative molding processes, and effective industry 4.0 concepts. Brand owners can expect high quality products at an excellent value, a fast response for decreased time-to-market, 100% inspection and traceability from pellet to pallet, supply-chain security compliance, and reliability from a trustworthy team. For more, visit www.westfall-technik.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210702005408/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
